Returns Chart

Key Stats

Customize
Expense Ratio Total Assets Under Management Dividend Yield Turnover Ratio
1.32% 189.58M 1.42% --
1 Year Fund Level Flows 1 Year Total Returns (Daily) Annualized All Time Total Returns (Daily) Max Drawdown (All)
-29.38M 14.86% Upgrade Upgrade

Basic Info

Investment Strategy
This fund’s objective is to obtain maximum long-term capital growth. It invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry. This includes companies that provide goods and services to these companies and companies that the portfolio advisor believes would benefit from developments in the health sciences industry.
General
Security Type Mutual Fund
Oldest Share Symbol CIG1701
Equity Style Mid Cap/Blend
Fixed Income Style --
Broad Asset Class --
Broad Category Equity
Category Name Sector Equity
Category Index Morningstar Gbl Mkts GR CAD
Prospectus Objective --
Fund Owner Firm Name CI Investments Inc
Prospectus Benchmark Index
NASDAQ Biotechnology TR USD 50.00%
S&P 500 Ind/Pharmaceuticals TR 50.00%
Broad Asset Class Benchmark Index
^SPTSX60TR 100.0%
Manager Tenure
Andrew Waight 23.87 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 100
-29.38M
-29.38M Category Low
351.56M Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of May 31, 2020

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of November 25, 2020. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2013
2014
2015
2016
2017
2018
2019
YTD
52.98%
10.59%
-3.13%
-15.74%
15.04%
-5.88%
18.95%
7.41%
13.26%
12.27%
-7.76%
21.36%
9.78%
-7.58%
21.93%
5.18%
10.33%
14.57%
5.27%
5.11%
10.71%
-11.27%
12.12%
4.34%
--
--
--
--
--
--
--
88.48%
41.23%
28.62%
21.67%
-10.02%
8.89%
6.23%
14.77%
9.08%
--
--
--
-6.71%
4.25%
12.62%
5.32%
6.67%
As of November 25, 2020.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (11-25-20) 1.42%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 18.42
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of May 31, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of May 31, 2020

Asset Allocation

As of May 31, 2020.
Type % Net % Long % Short
Cash 2.03% Upgrade Upgrade
Stock 97.97% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Alexion Pharmaceuticals Inc 6.10% 122.93 -0.15%
Takeda Pharmaceutical Co Ltd
5.95% -- --
Bristol-Myers Squibb Company 5.86% 62.84 -0.60%
Merit Medical Systems Inc 5.69% 54.92 0.26%
Intercept Pharmaceuticals Inc 5.45% 37.39 2.69%
Biogen Inc 5.35% 241.75 -0.31%
CVS Health Corp 5.24% 67.63 -1.17%
SeaSpine Holdings Corp 4.85% 14.31 1.63%
Ionis Pharmaceuticals Inc 4.73% 50.24 0.40%
Fresenius Medical Care AG & Co. KGaA
4.27% -- --

Fees & Availability

Fees
Actual 12B-1 Fee --
Actual Management Fee Upgrade
Administration Fee Upgrade
Performance Fee --
Switching Fee Upgrade
Transaction Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee --
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP Yes
Purchase Details
Open to New Investors Yes
Open to Existing Investors Yes
Minimum Initial Investment Upgrade
Minimum Subsequent Investment Upgrade

Basic Info

Investment Strategy
This fund’s objective is to obtain maximum long-term capital growth. It invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry. This includes companies that provide goods and services to these companies and companies that the portfolio advisor believes would benefit from developments in the health sciences industry.
General
Security Type Mutual Fund
Oldest Share Symbol CIG1701
Equity Style Mid Cap/Blend
Fixed Income Style --
Broad Asset Class --
Broad Category Equity
Category Name Sector Equity
Category Index Morningstar Gbl Mkts GR CAD
Prospectus Objective --
Fund Owner Firm Name CI Investments Inc
Prospectus Benchmark Index
NASDAQ Biotechnology TR USD 50.00%
S&P 500 Ind/Pharmaceuticals TR 50.00%
Broad Asset Class Benchmark Index
^SPTSX60TR 100.0%
Manager Tenure
Andrew Waight 23.87 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (11-25-20) 1.42%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 18.42
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of May 31, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of May 31, 2020

Fund Details

Key Dates
Inception Date 12/31/2009
Last Annual Report Date 3/31/2020
Last Prospectus Date --
Share Classes
CIG1401 --
CIG15005 Fee-based Advice
CIG16005 Commission-based Advice
CIG1701 Commission-based Advice
CIG18005 Institutional
CIG224 Fee-based Advice
CIG2924 Commission-based Advice
CIG2926 --
CIG324 --
CIG4924 Fee-based Advice
CIG886 Institutional
CIG90024 Commission-based Advice
CIG90324 --
Attributes
Enhanced Index Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No